Revenio: New iCare IC1000 strengthens core business competitiveness
Summary
- Revenio has launched the iCare IC1000, a new-generation handheld tonometer, enhancing its core business competitiveness by maintaining technological leadership and market dominance.
- The iCare IC1000 features improved ease of use and digital workflow support, including a GuideCam for better measurement alignment and a SmartCradle for data integration, aligning with Revenio's strategy towards comprehensive digital solutions.
- The device is not yet available in the US due to pending FDA approval, which is crucial as the US is considered Revenio's most important market.
- While traditional tonometer sales growth is slowing, product innovations like the iCare IC1000 are vital for sustaining market position and ongoing probe sales.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 9/10/2026 at 11:41 am EEST.
On Thursday, Revenio announced the launch of the new-generation handheld iCare IC1000 tonometer. We consider the launch of the new device generation to be a natural and important step in the product development of the company's core business, as it helps the company maintain its technological lead and defend its market leadership. The news is in line with our expectations regarding the company's continuous product development, and the product launch does not cause immediate changes to our forecasts.
New features support workflow digitalization and ease of use
According to the release, the new iCare IC1000 retains the key benefits of the company's rebound technology (RBT), such as being painless, quick, and not requiring anesthesia. The most significant differences from previous models relate to improved ease of use and support for digital workflows. The device features a new GuideCam alignment, which visually guides the user to find the correct measurement position. We believe this feature will further lower the threshold for adopting the device and reduce the variation in measurement results between different users.
In addition, the device was introduced with the new SmartCradle, which, alongside charging the device, enables smoother data transfer and the integration of measurement results into the iCare software ecosystem. In our view, this is a clear indication of the progress of Revenio's strategy: the company aims to move from a mere equipment manufacturer towards more comprehensive digital solutions and seamless care pathways.
Strengthens core business competitiveness, US market still awaits FDA approval
In our estimation, bringing the new device generation to the market is important for Revenio so that the company can maintain the high gross margins of its products and respond to the challenges brought by competitors' RBT technology. Device availability will initially vary by market, and it is not yet on sale in the United States, where the required FDA review process is ongoing. We consider the US to be the company's most important single market, so we are following the progress of the FDA clearance with interest. Overall, we believe the iCare IC1000 is an important addition to the company's product portfolio. Although the growth of device sales in traditional tonometers is slowing down over the longer term, product renewals of this kind are critical to safeguarding a strong market position and continuous probe sales.
Login required
This content is only available for logged in users